: These findings from a prospectively defined analysis of a large randomized trial confirm CD56bright NK cell counts as a DAC HYP efficacy biomarker and further support their immunomodulatory role in RRMS. http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/S31.004 RRMS is relapsing and remitting multiple sclerosis. This is the same biomarker PHANU have found in cfs/me. I dont quite understand this study, i think its saying those with a better nk bright cell numbers had fewer lesions. Daclizumab HYP Treatment is a monoclonal antibodies and this improves nk bright cells?? Could this DAC HYP be a treatment to improve nk function in cfs/me?? Trying to find more on this DAC HYP if someone can help me out? ALso someone with a better mind then me could make more sense of the study for the rest of us to understand would be great too?